Ferring

SAINT-PREX, Switzerland, August 31, 2011 - - Rapid and sustained testosterone suppression and improved PSA control may delay time to second-line therapy New data, published in the September issue of TheJournal of Urology, showed that long-term use of FIRMAGON (degarelix) a gonadotropin-releasing hormone therapy (GnRH) approved for the treatment of advanced prostate cancer in both the EU and US, continued to be effective and well tolerated beyond three years.[1] The new study (CS21A) extends the conclusions of the pivotal Phase III study (CS21) in which the risk of prostate-specific antigen (PSA) failure or death was significantly lower in patients on FIRMAGON compared to leuprolide (an LHRH agonist) up to one year.[1] The extension study has now shown that for patients who remained on FIRMAGON, PSA suppression and the effects on PSA progression free survival (PFS) remained consistent over the long term (42 months).[1] In addition, the study looked at patients who crossed over from leuprolide to FIRMAGONafter one year.

VIENNA, Austria, March 21, 2011 - Recent data from the ongoing five-year FIRMAGON(R) (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of FIRMAGON(R) in study patients with advanced hormone-dependent prostate cancer and support its use as first-line androgen deprivation therapy.[1] Full details were shared today at the European Association of Urology (EAU) 2011 Annual Meeting.